Loading…
Loading…
TRVN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TRVN and 80,000+ other tickers.
See exactly how TRVN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TRVN and 80,000+ other tickers.
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid…
Trevena, Inc. (NASDAQ: TRVN - Get Free Report)'s share price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $0.01 and traded as high as $0.0111. Trevena shares last traded at $0.0111, with a volume of 594 shares. Trevena Stock Performance The company has
Profitability This table compares Trevena and Ampio Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Ampio Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Trevena and Ampio Pharmaceuticals"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition Corp. Patria Latin American Opportunity Acquisition Corp.'s Class A ordinary shares were suspended on March 19, 2025. On November 18, 2024, Patria Latin American Opportunity Acquisition Corp.'s warrant and unit were suspended. None of these securities have traded on Nasdaq since the respective suspension dates.
After losing some value lately, a hammer chart pattern has been formed for Trevena (TRVN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates.